Given Imaging Announces Major Presence at Three Scientific Conferences

• The American College of Gastroenterologists
• United European Gastroenterology Week
• Australian Gastro Week

60 Studies Presented Involving Nearly 1700 Patients Confirm That The M2A Capsule Endoscope Is Changing Clinical Practice

17 October 2002 - YOQNEAM, Israel -- Given Imaging (NASDAQ: GIVN) announced that with 40 clinical presentations, 21 lectures and an off-site symposium on capsule endoscopy, it will have a strong presence at the 10th Annual United European Gastroenterology Week (UEGW) in Geneva, Switzerland, the American College of Gastroenterologists (ACG) Annual Meeting in Seattle, Washington, and the Australian Gastro Week (AGW) this month. Data on nearly 1700 patients will be presented showing superiority of capsule endoscopy over conventional diagnostic methods in diagnosing diseases of the small bowel including cancer, Crohn’s disease, gastro-intestinal bleeding, inflammatory bowel disease and celiac.

"The growing number of peer reviewed publications and clinical presentations at leadership forums such as the ACG, UEGW & AGW evidence how our M2A capsule endoscope is changing clinical practice in gastroenterology and is the accepted diagnostic standard of care for the small intestine," said Gavriel Meron, president and chief executive officer of Given Imaging. "Most importantly, the M2A is changing the way physicians manage their patients’ treatment and allowing them to improve patients’ lives through earlier and better diagnosis."

ACG: OCTOBER 20th - 22th

Given Imaging will exhibit at the ACG annual meeting in exhibit hall 4 at booth # 207. Full details about Given’s presence at ACG are provided on the Company’s website at http://www.givenimaging.com/site/acg/clinical_symposium.asp Editor's Note: This link is no longer active.

Among the highlights are the following:

• Clinical presentations discussing the M2A capsule’s high level of sensitivity in detecting small bowel cancer;
• Several clinical presentations showing the superiority of capsule endoscopy in the small intestine to conventional modalities such as push enteroscopy, ileoscopy, enteroclysis, small bowel follow through, CT scans for a broad range of indications; and
• Three clinical presentations on the ability of the capsule endoscope to diagnose Crohn’s disease.

UEGW: OCTOBER 19 - 21

Given will host exhibition booth #1160 at the conference. Full details regarding Given Imaging’s presence at UEGW are available on the company’s website at http://www.givenimaging.com/site/uegw/clinical_symposium.asp Editor's Note: This link is no longer active.

Among the highlights of the 25 clinical trials with a total of over 900 patients having ingested the M2A Capsule are:

• A broad spectrum of emerging clinical applications of capsule endoscopy in patients with suspected small bowel disease, including proposed surveillance of patients with increased risk of small bowel tumor;
• Four trials that confirm the superior diagnostic yield of the M2A capsule endoscope in the small intestine in comparison to x-ray and conventional endoscopy;
• Five clinical presentations that demonstrate the beneficial use of the M2A Capsule in Crohn´s disease both for initial diagnosis, for confirming the diagnosis when only suspected by other methods and for evaluating the extent of the disease in the entire small intestine;
• Two trials showing the M2A Capsule Endoscopy to be effective, safe and painless for detection of small bowel diseases in HIV positive patients; and
• A company sponsored clinical symposium which is not associated with UEGW on Tuesday, October 22 in the Hotel Intercontinental at 18:30 - 20:15 : M2A® Capsule Endoscopy - Changing Clinical Practice.

This press release contains forward-looking statements, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," "intends" and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

CONTACT:
Scott Fraser of Given Imaging, +1-770-810-0926;
Fern Lazar, flazar@lazarpartners.com, or David Carey, dcarey@lazarpartners.com, both of Lazar Partners, +1-212-867-1762